Ezatiostat, a GSTP1 inhibitor, and RSL3, a GPX4 inhibitor which has been reported as a novel strategy to prevent tumor relapse [26], reduced cell viability of both parental and TKI-resistant cells (Table 1) with an IC50 in the low μM range unveiling glutathione metabolism as a putative target for the management of TKI resistance. Here, GSTP1 is linked to neoplasm.